Apollomics (APLM) Other Accumulated Expenses (2022 - 2025)
Apollomics (APLM) reported Other Accumulated Expenses of $6.1 million for Q4 2025, down 52.23% quarter-over-quarter from $12.8 million in Q2 2023.
Apollomics (APLM) Other Accumulated Expenses (2022 - 2025) Analysis & Trends
Apollomics (APLM) has 3 years of Other Accumulated Expenses data on file, last reported at $6.1 million in Q4 2025.
- Other Accumulated Expenses for Q4 2025 came in at $6.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $6.1 million (changed N/A YoY), and the FY2025 annual result was $6.1 million, changed N/A from the prior year.
- Other Accumulated Expenses eased to $6.1 million in Q4 2025 per APLM's latest filing, from $12.8 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $12.8 million in Q2 2023 and troughed at $6.1 million in Q4 2025.
- A 3-year average of $10.2 million and a median of $11.7 million in 2022 frame the typical range for Other Accumulated Expenses.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Apollomics | 294.00 Mn | 294.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.12 Mn |
| Jun 30, 2023 | 12.80 Mn |
| Dec 31, 2022 | 11.68 Mn |